Q3 2024 GSK PLC Earnings Call
[inaudible]
[inaudible]
[inaudible]
The End
Speaker Change: 9% as you can see from the chart here, two three cells growth reflected a tough comparison with strong growth from specialty and gen meds are sitting the low cells of vaccines.
Speaker Change: Specialty medicines, the largest part of our business grew 19% reflecting strong performance of new products and the investment we have put into recent launches particularly in oncology and HIV.
Speaker Change: We expect this moment to continue with growth from these assets and several material launch opportunities and respiratory oncology and other disease areas coming later next year.
Speaker Change: General Medicine's Police Society cells were up 7% driven by strong performance of respiratory and has already been mentioned lower demand for Schingricks and Eurexphides' quarter lead to an overall cells decline of 15% of accents and I'll cover this in more detail in a minute.
Speaker Change: All these dynamics were broadly reflected in the performance of our regions, with good growth internationally and the US, unsurprisingly, was more impacted by the lower vaccine demand we saw this quarter. Please turn to slide 11 to look at vaccines in more detail.
Speaker Change: So I'll focus the commentary on a rectifier in the chamber. A rectifier of performance was impacted by three factors. Firstly, by changes in ACIP guidelines that restricted the recommended populations of older adults receiving RFV vaccinations.
Speaker Change: Secondly, by prioritization of COVID vaccinations in the U.S. And thirdly, by a lower seasonal rate of RSV infections.
Speaker Change: In addition, it was a tough comparator given two-thirds of sales in Q3 last year were related to stocking.
Speaker Change: Despite these dynamics, we retained our strong leadership market share.
Speaker Change: Now we're still in the foothills of this vaccine's availability and usage. In the U.S. we continue to make data available to ACIP and to support them as they move towards making longer-term recommendations on the use of RSV vaccines, including requirements for revaccination and cohort expansion.
Speaker Change: Beyond the U.S., Areci is now launched in 35 markets, 16 with national recommendations and six with national reimbursement programs. More rollouts across Europe and international will come in 2025.
Speaker Change: For Shingrix, year-to-date growth was driven outside the U.S., now 58% of the business, and the average immunization rate across the top 10 markets excluding the U.S. is still around 6%, so there's still a large opportunity here.
Speaker Change: Growth outside the U.S. was 9% this quarter, and U.S. penetration was 39% at the end of the second quarter. Adding to U.S. penetration remains a key focus, but the pace is slowing from around 6 to 7 points per year.
Speaker Change: to around three to five points per year, making incremental growth more challenging. And if you take a look, the visual on this slide also shows how U.S. cells moderate as the immunization rate slows. Next slide, please.
Speaker Change: Thanks for watching!
Speaker Change: So looking ahead on vaccines, this year we now expect vaccine sales to decline low to single digits and in 2025 we expect limited growth, reflecting the assumption that there will be no orexy revaccination or expansion of age cohorts next year.
Speaker Change: Beyond 2025 for Rexvi we expect further successful rollout and that public health recommendations for cohort expansion and revaccination will be confirmed alongside international penetration given the patient need and the protection this vaccine can offer against RSV.
Speaker Change: And so on this basis, we continue to expect OREXFY to make a significant contribution to future sales and we continue to believe it can achieve peak sales of more than three billion pounds. For Shingrix, our ambition remains to achieve more than four billion pounds in sales.
Speaker Change: And finally, beyond Orexphe and Shingrix, we also have material growth opportunities with mRNA and our MAPS technology, where we've decided to prioritise a pneumococcal 30-plus valent asset in adults to pursue the broadest potential coverage.
Speaker Change: and further build out of our meningitis portfolio the next step of which will be the launch of our MenABCWY vaccine in 2025. Next slide please.
Speaker Change: Specialty meds is an increasingly important driver of our growth for GSK reflecting the combination of successful R&D and BD investment over the recent years and it's delivered another quarter of excellent growth including HIV which Deborah will cover shortly.
Speaker Change: Respiratory and Immunology products were up 14%.
Speaker Change: and Nucala IL-5 biologic treatment was up 12%. In September, we announced positive headline results from MATIN-A, a phase three trial evaluating Nucala in adults with COPD, a disease which affects more than 300 million people.
Speaker Change: and the full results will be presented at a Scientific Congress next year.
Speaker Change: We also presented SWIFT Phase III data for our ultra-long-acting IL-5 treatment, Depamocumab, in the quarter. And Depamocumab demonstrated a 54% reduction in exacerbations versus placebo, plus standard of care for patients with severe asthma after only two injections in a 12-month period.
Speaker Change: This is a major benefit for provider and patient. In addition, positive data from the phase 3 anchor study evaluating Depimocumab in patients with chronic rhinocytis with nasal pulse was also announced this month.
Speaker Change: Alongside SWIFT, these data will support expected filing before the end of the year with a view to a dual indication launch in 2025. And to remind you, combined, we expect our IL5 portfolio to deliver more than four billion pounds in peak year sales.
Speaker Change: Ben Lister is up 16% in the quarter with strong demand and volume growth in all regions and oncology almost doubled which I'll cover in more detail on the next slide.
Speaker Change: We expect momentum in this part of our portfolio to continue, especially given the launch opportunities we have in front of us, and for this year we're upgrading sales expectations for specialty medicines to high teens percentage growth. Next slide please.
Speaker Change: Focusing on oncology, sales almost doubled in the quarter and we've delivered more than 1 billion pound in turnover so far this year. Our focus on hematology and gynecologic cancers is delivering strong progress evidenced by the success of new product launches in these areas.
Speaker Change: Ajara, which has launched in the US, Europe and very recently in Japan, has seen quick adoption with high quarter-on-quarter growth and in the US it's maintaining its fast launch uptake and there's still a large opportunity remaining in first line.
Speaker Change: Dr. Smith, Dr. Smith, Dr. Smith,
Speaker Change: Gemperli cells also continue to grow strongly. In August, the US FDA approved Gemperli plus chemotherapy for the treatment of adult patients with primary, advanced, or recurrent endometrial cancer. This approval broadens the previous indication to include the 70 to 75 percent of patients diagnosed with endometrial cancer who have mismatched for hair-proficient, microstatelite-stable tumors.
Speaker Change: And treatment options have been limited for this cohort, so it's important Gemperli is now available to these patients.
Speaker Change: Zajula's growth continued in Q3, driven by U.S. pricing effects and high demand outside the U.S.
Speaker Change: And looking ahead, we have a significant opportunity to strengthen our oncology business with the launch of BlendRep in half to 2025. We file for approval in the U.S., EMA, and Japan in the quarter. Next slide, please.
Speaker Change: General Medicines grew 7% in Q3, primarily driven by Trilogy, and Trilogy sales increased 16% to 600 million pounds with strong growth across all regions, reflecting patient demand, class growth and increased market share in the overall asthma and COPD market.
Speaker Change: Use of authorized generic versions of Advair and Flovan, continuing to fully offset the removal of the AMCAP on Medicaid drug prices in the US.
Speaker Change: And given our stronger performance this year, we now expect mid-single-digit percent sales growth for general medicines this year.
Speaker Change: Looking forward for the total business, the U.S. is expected to face pressure from the implementation of the U.S. Inflation Reduction Act legislation in 2025.
Speaker Change: And we expect the overall impact of this range to be around 400 to 500 million pounds, including HIV. I'll now hand over to Deborah.
Deborah: Thank you Luke, now turning to HIV. We continue to deliver strong performance and sustained double-digit growth with Q3 sales of 12%.
Deborah: This growth was driven by strong patient demand as well as favourable pricing dynamics.
Deborah: For 2025, we do not expect the favourable pricing dynamics to continue, in part due to the introduction of the Inflation Reduction Act. However, we are confident that the underlying demand for our medicines will remain strong.
Deborah: Thank you.
Deborah: As leaders in oral-to-drug regimens and long-acting injectables, it is positive to see this continued momentum delivering two percentage points of market share gain versus the previous year.
Deborah: Devato grew 23% for the quarter
Deborah: This positive growth was supported by results announced in July from the Pasaduble study, a large head-to-head randomized clinical trial of Dovato compared against the three-drug regimen Victavi.
Deborah: This study demonstrates DeBarto's non-inferior efficacy and significantly less weight gain versus Biktavi.
Deborah: This is important because we know people living with HIV are concerned about taking more medicines as they age, as well as the long-term risk of metabolic diseases that can come with weight gain.
Deborah: The performance of our long-acting portfolio also remains positive, delivering £314 million of sales and representing more than 50% of total growth for the quarter and year to date.
Deborah: Cabanuva grew 40% driven by patient preference and proven and durable efficacy. The medicine now holds a market share of 5% or more in the majority of our key markets demonstrating sustained quarter-on-quarter growth.
Deborah: Apertude, the first and only approved long-acting option for HIV prevention, delivered 95% growth in the quarter.
Deborah: At the ID Week conference earlier this month, we shared real-world evidence reinforcing the more than 99% effectiveness for apertude, as well as an implementation study highlighting patient-reported results with a reduction in stigma and anxiety.
Deborah: Looking further ahead, we are strongly focused on developing our ultra-long acting pipeline. This includes development of new regimens for four-monthly dosing with ambitions to extend to six-monthly dosing.
Deborah: The potential for the long-acting market remains significant.
Deborah: The total HIV market today for treatment and PrEP together is worth more than £22 billion, with treatment accounting for around 90% of this, and we believe treatment will continue to be the larger market going forward.
Deborah: We are the leaders in long-acting innovation and are confident in our innovative pipeline for the future as well as the competitive profile of our medicines today, offering strong safety, efficacy and overall tolerability for people living with HIV and those who could benefit from PrEP. With that, I will hand to Julie.
Julie: Thank you, Deborah, and good morning, everyone. Next slide, please.
Julie: Building on the comments made by Luke and Deborah, this slide shows specialty medicines is an increasingly important growth driver for the group, having delivered more than 70% of year-to-date growth.
Julie: This has been supported by building scale and momentum in our respiratory, immunology and oncology businesses. And although vaccine growth has been limited this year as Luke outlined, longer term we are very confident in this opportunity. Next slide please.
Julie: Moving to the income statement for the third quarter with growth rates stated at CER, sales increased 2% reflecting continued strong momentum especially from specialty medicines but also general medicines more than offsetting the decline in vaccines.
Julie: Core operating profit grew 5% despite the significant decrease in Gardasil royalties.
Julie: Growth margin benefited from the outperformance of high-margin specialty medicines, pricing benefits, and the annualization of prior year inventory provisions.
Julie: The decline in SG&A spend resulted from our disciplined approach to investment, the annualization of high prior year launch investments, and the phasing of spend across half too.
Julie: The Gardasil Royalty loss impacted profit growth by minus 8% this quarter, meaning underlying operating profit was up 13%, demonstrating considerable productivity improvements in Q3.
Julie: Core EPS grew 5% excluding COVID in line with the operating profit growth.
Julie: And turning to the total results, operating profit decreased materially year on year from 1.9 billion pounds last year to 0.2 billion this year.
Julie: The reduction predominantly reflected a 1.8 billion charge relating to the resolution of the Zantac litigation.
Julie: Moving to our margin bridge with commentary including COVID. Our Q3 core operating margin increased 100 basis points year-on-year at CER to 35%.
Julie: Despite 180 basis point headwind from the loss of royalties as we continue to deliver on our financial commitments and drive leverage within the business.
Julie: The strong underlying accretion was supported by three factors. First, the outperformance of specialty medicines where the portfolio is driven a positive mixed impact in gross margin and considerable operating leverage resulting from the strong sales growth.
Julie: Secondly, the annualization of prior year inventory provisions in cost of goods and loan to investments within SG&A.
Julie: and third the phasing of SG&A spending with a greater weighting expected towards Q4 this year. Next slide please.
Julie: Thanks for watching!
Julie: Year-to-date cash generated from operations was 5.3 billion, representing an improvement of 0.9 of a billion compared with last year.
Julie: and this was primarily driven by improved operating profits and a working capital benefit compared with last year, benefiting from higher ERECSPI collections earlier in the year.
Julie: Other CGFO was lower due to returns and rebates, partly offset by lower pension contributions.
Julie: Free cash flow was £1.9 billion, improving compared with the £1.3 billion last year, with improved CGFO, partly offset by higher tax and higher business development, including acquiring full rights to flu and COVID mRNA from CureVac.
Julie: Next slide please.
Julie: Slide 22 shows our net debt position since the 31st of December and how we've actively deployed capital in the business in line with our framework.
Julie: Net debt in September was £13bn, a reduction of £2bn compared with December 23, given the strong free cash generation and the hailing monetisation.
Julie: Through the nine months we have deployed capital to strengthen the pipeline and platforms through business development and as recently announced we have expedited retiring the risk from VANTAC.
Julie: We expect this to result in a 0.8 of a billion pound cash outflow in Q4-24, with the remaining £1 billion being paid in the first half of 2025 and included in CGFO.
Julie: There is no change to our capital allocation priorities. We have a strong balance sheet which provides optionality to accelerate further growth organically and through business development as we look to deploy funds to enhance growth and deliver attractive shareholder returns.
Julie: And with that, I will now turn to our full year expectations. Next slide, please.
Julie: range of 79% sales growth and 11 to 13% profit growth, and expect to land broadly around the middle of these ranges, notwithstanding the loss of Gardasil royalties.
Julie: which we expect to reduce profit growth by six percentage points this year.
Julie: Core earnings per share is expected to grow at 10-12%, slightly below operating profits due to an increase in the tax rate under the OECD legislation.
Julie: We will update you on our view of 2025 next year, but as importantly, we remain very confident in achieving our great growth outlook for 'twenty, one 'twenty six of more than 7% sales growth of more than 11% core operating profit growth will be at the shape of this could be more weighted to specialty medicines reflect.
<unk> expected performance in summary, we have delivered another quarter of growth, reflecting the breadth of our portfolio and the building momentum in specialty base.
Julie: Based on the pipeline progress, mainly I'm very confident in achieving our full year guidance as well as our medium and longer term outlooks next slide please.
Julie: Turning to our IR roadmap significant progress has been made towards major milestones and finally, one locks I've also highlighted here the five major regulatory approvals expected next year across three therapeutic areas.
Julie: We also look forward to our next meet the management event at the end of the year, which will be the first introduction to some of our early stage pipeline and with that I am pleased to hand back to Emma to conclude.
Emma: Thanks, Julie so to summarize.
Emma: While Q3 has presented some challenges our business has responded well and we are on track to deliver our strong sales and profit guidance for 2024.
Looking ahead, we have a best in class vaccine business and increasingly strong and growing specialty business in a very profitable Gen merch business together and combined with the momentum we continue to see in our pipeline and our careful but meaningful deployment of capital into business development. This means we're well positioned to deliver sustained profitable growth.
Emma: Through the decade.
Emma: Scale health impact and attractive returns for shareholders.
Emma: All of this by combining science technology and the talent of Gsk's people to get ahead of disease together.
Emma: But that's that's now open up the call for Q&A with the team.
Speaker Change: Okay. Thank you for the Q&A portion of our call. Please use the handbrake feature and assume webcast. If you would like to ask a question and as a reminder, we ask that you limit yourself to only one or two questions. So that we may accommodate as many participants as possible for our first question will.
Speaker Change: Go to James Gordon James.
Speaker Change: Please UN mute yourself.
James Gordon: Hello, John Jordan.
James Gordon: Thanks for taking the questions. One question was on the cocoa vaccine. So affiliate banks. So I think you did have a 24 valent, although and then I think that's been the losing of switching 30 pilots. So just what is the latest in terms of operating discipline device put a couple of them. This is disconnected too.
James Gordon: Vaccine had some competitor data of the 31 available.
James Gordon: As it is.
James Gordon: Today's the pediatrics in the adults. They go both shipped against you, but that's the first question. Please.
James Gordon: The second question would be 25% with a few comments in 'twenty five.
James Gordon: Thinking about 25 should we think that maybe <unk> might be down but also you could have some further significant SG&A leverage.
James Gordon: Performance of next Gen <unk> today.
Speaker Change: We need to think about your spending on SG&A, because you've got new launches next year.
Speaker Change: Greg.
Speaker Change: Firstly at the time of day.
Speaker Change: On the pneumococcal update very much like this they'll get to the best in class vaccines as we have with our current portfolio and then myself continue will come back on the on the guidance question.
Speaker Change: Thanks for the question James Let me just start by sort of underscoring the platform in general and I would say that as we learn more about our platform, we become more and more confidence in the fact that 8%.
Speaker Change: Unique proposition to add his comments about best in class and it does so because it provides both coverage and to chili's in particular.
Serotype, three because it's a carrier protein proposition.
Speaker Change: It does so without the diminishing immunogenicity that you see in the CRM based platforms, which as you add antigen coverage.
Speaker Change: Immunogenicity to initiatives, we have strong competitors.
Speaker Change: For.
Speaker Change: For investors, both the 20 and 13 failure the PCV vaccines Youre right, we have shifted our prioritization and the adult vaccine towards <unk> <unk> plus.
On proposition and not us.
Speaker Change: Initially you will recall of course the box sites are in the similar position, but look 21 days in vaccine, which casualty chose serotypes established.
Speaker Change: Vaccine efficacy ceiling against those chosen serotypes in the adult population that we believe makes the 30 plus proposition think most effective one I think you see that reflected in the size of the strategy. Tom described guests stay as well.
Speaker Change: I would just say I remain confident in the office each of our thoughtful and based on the data that we're recruiting and I expect bill to start.
Speaker Change: Plus adult first in human study Nextgen as far as with Pediatrics proposition is concerned we remain developing both 24 and 30 plus.
Speaker Change: Vaccines in that context and what.
Speaker Change: Confident about the competitive setting for both 2030, plus vaccines with regards to ultimate launch states, although we have not disclosed those in detail.
Speaker Change: Thanks, Tony.
In terms of looking into 'twenty fives, I mean, obviously, we're going to guide for 2005.
Speaker Change: 25, but I'll ask Judy just to recap a little bit on some of the points. We've made on the individual product areas to help too, but also our confidence in the shape of.
The P&L too because make no mistake, we expect <unk> to be another year of profitable growth for the company and we are very confident in our 26 outlook I don't think she won the outlooks of more than.
Speaker Change: 7% top line growth more than 11% bottom line growth more than 38 billion and again.
Speaker Change: Yes includes blend rate, while we've made great progress based on the data we're looking forward to getting overall survival later on this year.
Speaker Change: And we filed.
Multi regions.
Chad.
Speaker Change: Looking to 2025, the commentary, we expect headwinds from our largest product area of specialty just to continue to lead the way.
Speaker Change: We have a mix comments.
Speaker Change: Made assumptions to be conservative.
Speaker Change: Around any judgment, so that there will be no change.
Speaker Change: Next year, obviously, we're dependent on them.
Speaker Change: But in terms of.
Speaker Change: The re fracs or I hope that we continue to bring data.
Speaker Change: He can comment more on that.
Speaker Change: But make no mistake medium term, whether it be in our confidence of growth space.
Speaker Change: Shang links.
Speaker Change: Ex U S.
Speaker Change: The RFP, which is really in the very early days.
Speaker Change: Its lifecycle well because of the pipeline that's coming through put a name of coca commentary or mrna or very excitingly.
We are seeing across specialty medicines with five approvals that know about.
Speaker Change: Just coming through in 'twenty, five, but driving more price.
Speaker Change: That's about to be honest in the decade. So generally I think there are other specifics ill, let you recapping and particularly also those lines in the P&L.
Speaker Change: We're starting to drive some powerful leverage yeah sure. Thank you very much.
Speaker Change: Thanks for the question. So I think it was.
Speaker Change: Thank you, ladies and gentlemen, currently there.
Speaker Change: Vaccines.
Speaker Change: I would just like to draw your attention to the specialty medicines business is now our biggest basis, it's 37% of our basis any trends more than 17% of our growth.
Year to date.
Speaker Change: As being one of the major contributors to the point you raised about the leverage and leveraging the P&L. So we've just delivered year to date, 9% on the top line, 19% on the Prophage is absorbing the door locks as.
Speaker Change: As well and there are a number of important therapeutic areas driving that.
Speaker Change: Obviously, HIV respiratory immunology and <unk>.
Speaker Change: Oncology as mentioned our oncology business has more than doubled here today too.
Speaker Change: Over $1 billion, so turning to 2025, when <unk> coming from.
Speaker Change: When you call up and listen we've obviously got COPD to come when you call out having just been.
And then <unk> and then we've got the oncology strength coming from Jessica Li X by the population under Jarrod and then hopefully blend that following the recent submission.
In terms of the P&L.
Speaker Change: Leverage as you can see yesterday, we've delivered very strong gross margin leverage again. This is being benefited from specialty care and we continue to see the gross margin being strong apart from this fourth quarter, where we're going to put these additional charges through to drive future supply chain efficiencies.
Speaker Change: And then in terms of the launches Nextgen Zander mentioned, we've got five regulatory approvals and launches coming across vaccines special fee on general medicines. They are in our four key therapeutic areas, where we've already got a strong presence at risk.
Speaker Change: Phase III vaccines.
Speaker Change: Its also now in oncology. So therefore, you can expect us to continue to deliver profitable growth.
25 of them acquainted mentioned thank.
Speaker Change: Thank you next question please.
Speaker Change: Next question is going to be from Kerry Holford Terry.
Speaker Change: On mute yourself.
Speaker Change: Thanks, Jeff.
Speaker Change: Yes, Gary else's in there Doug.
Kerry Holford: Two questions from me please.
Kerry Holford: In Shanghai in China, I Wonder if you can comment.
Kerry Holford: And the same is going to be spending.
Kerry Holford: Great.
Kerry Holford: And also just remind us.
Kerry Holford: Details of that contract mix it day and night.
Kerry Holford: Okay.
Speaker Change: No there's none.
Speaker Change: You had mentioned previously began one suite to three and a set in stone or is there some degree of flex within that.
Speaker Change: Yeah.
Speaker Change: And then secondly on the spirit trade specific D&C a P J.
Speaker Change: When might be you might get to see the detailed phase when you call it.
Speaker Change: And previously you won't make that if you've got a positive result here.
Speaker Change: Would swiftly move <unk> into.
Speaker Change: Into phase III is obviously your current thinking.
Speaker Change: Now is the piece that opportunity going to take a more important role in our space or to say.
Speaker Change: Anything.
Speaker Change: So I'll come to tie to me first on the IL five pipeline.
Speaker Change: We are very excited about them and then we'll come to Luke to comment on where we're at with China remembering.
Speaker Change: Several of our degree of macro pressures here so it looks like.
Speaker Change: A great partnership there and we're trying to take a long term deal that maybe it would be good if you could update on where we're at.
Speaker Change: For the first time in Ta. Thanks for the question. Let me just begin by reminding everyone that recall is the first and only biologic conclusions for different year.
Speaker Change: Diseases.
Speaker Change: We showed with the massenet headline data, we will show a semester matson, a headline and pulling the data or you said it reduces.
Speaker Change: Exacerbations across the full spectrum in COPD patients.
Speaker Change: Youll get more detail on that Terry.
Speaker Change: In the first half of next year at an appropriate conference obviously until we got approvals of <unk>.
Speaker Change: The abstract so I can't give you details on that but the important point to stress there is that it.
It is the growing our performance of new color illustrated to vaccinate across COPD population on my might also take the opportunity just to remind everyone that what we said in the past.
Speaker Change: Comparison with <unk>, it's important to consider that the population studied.
Speaker Change: And metrics.
Speaker Change: <unk> and <unk> are different to the two populations, where it takes some of the broader.
Speaker Change: Broader COPD population, including female patients.
Speaker Change: And of course, that's important when one considers that COPD is the third leading cause of death.
Speaker Change: Worldwide, and 300 million people will have COPD and a significant proportion of those some of the highest defense if I remember correctly.
Speaker Change: So more from us on your color on the details of that at the beginning or the.
Speaker Change: Middle of the next year or so.
Speaker Change: I indicated and then what I would highlight in terms of what follows from that with regards to the next wave portfolio funds, obviously it positions.
Speaker Change: Very favorably.
Speaker Change: <unk> also already is that office is significant.
Speaker Change: Vantage than two injections per year versus 26 in the comparison with <unk>.
Speaker Change: Also very pleased and you'll hear more about this management that we have long acting options in both T Slim and IL 33, So what we will disclose to you. There is how we think about positioning those three long acting options into.
Speaker Change: Understanding of the subgroups of COPD disease.
Speaker Change: Got it.
Speaker Change: Hi, yes, thanks Kerry.
Speaker Change: On the Q2 call.
Kerry Holford: We did flag that we're concerned about.
Kerry Holford: I would watch closely what's occurring in China, particularly intense.
Kerry Holford: The budgets to.
Kerry Holford: Some of the flow of funding around those and of course, the macro which is.
Kerry Holford: Just very broadly covered.
Kerry Holford: Across many industries.
Kerry Holford: And so we're actually seeing that.
Kerry Holford: Definitely impacts caused a slowdown in the economy definitely impacts the salt.
Kerry Holford: Market.
Speaker Change: So I just the capacity of local governments to then raise stock purchase vaccines, which are then subsequently.
Speaker Change: Just by individuals. So these are having an effect on our volumes.
Speaker Change: We're working closely with Jeff.
Speaker Change: Again, if we look at the medium to long term I mean, the partnership has started extremely well.
Speaker Change: These are impressive operators they have gone through a number of points of vaccination and we can get to with our infrastructure.
Speaker Change: You asked what we saw would start around 240 billion out of the 0.4 that we had in the contract there is flex in the con practical despite a site.
Speaker Change: Our intent is to be practical hands.
Speaker Change: Worked through this was hit by it but we have our eyes on the long term opportunity of about half a billion people in China, who are 50 plus.
Speaker Change: That's where the focus is at this point.
Speaker Change: Next question. Please our next question is from Jo Walton Joe.
Speaker Change: Okay.
Jo Walton: Thank you.
Jo Walton: I'm going to just ask a broader question about IRI on the precious that we might experience next year some of the pushes and pulls here.
Jo Walton: We've already seen some companies show higher prescription growth as they go through the year and it's notable for unlisted going up six nine and then 14% is any of that to do with.
Jo Walton: Already experiencing lower people already experiencing lower co pays could that be a benefit to you going forwards.
Jo Walton: You've talked about pressures in the past.
Speaker Change: Respiratory, whereas the authorized generic soar and you've done to say well, presumably payers are not getting the rebates that they want are you seeing more precious for rebates elsewhere, you must be a long way through your negotiations for next year. So you should be able to tell us how your expectations are for axis.
Speaker Change: Going forwards.
Speaker Change: A second question if I could please could you just tell us a little about our base about RSV ex U S is that really not an opportunity Utah until the dosing has been sorted out. Thank you.
Speaker Change: So.
Speaker Change: So that's come to you when we get to flat.
Speaker Change: <unk> hundred overall, NRI, and then RSV ex U S. Yes.
Speaker Change: There is increased pressure there I think pbms Hogan looking for.
Speaker Change: Setting that amount I think were starting to see tactical decisions by physicians in terms of trying to push people through.
Speaker Change: That coverage and I think that's across the whole portfolio, specifically for us I mean with 340 <unk>.
Speaker Change: Nine states legislation, there's another 10, which are working on it so that impacts specialty.
Speaker Change: There is also some impact on vaccines of course, but they tend to benefit in aggregate because of the removal of.
Speaker Change: The other thing that particularly with trilogy, while it is the trilogy, driven element, which is this $35 copay, which will have an effect.
Speaker Change: Next year, and then longer term with trilogy, we expect it to be listed next year I think the government has lines.
Speaker Change: Through the first round, particularly around the influence.
And dynamics of the coverage gap. So we expect more pressure on pricing and that will flow through with trilogy in 'twenty six 'twenty seven, but we think we can start to return to growth.
Speaker Change: After that with trilogy and of course ex U S.
Speaker Change: It continues to do well.
Speaker Change: The areas, where we tend to see fresh were 340, <unk> products like solar and new column, specifically on new collar I think it's more driven by with starting to pivot and to look at nasal polyps. It's been very successful in Europe, we've been a little bit.
Speaker Change: There's a little bit slower in the U S to pivot to that and now we're really aggressively looking at that and saying very good feedback and the e&ps are certainly.
Speaker Change: Willing to experiment with this with this molecule.
Speaker Change: And we've seen I mean.
Speaker Change: We tested it in markets like Italy is for a fantastic surge.
Speaker Change: Carla So thats what were now ramping up.
Speaker Change: Key markets globally, with new cough, and RSV ex U S sure.
Speaker Change: I think now we know enough about this back saying that we need to move forward.
Speaker Change: The feedback we're getting.
Speaker Change: Is there a encouraging sneak just did a broad RSV vaccine contract in Germany at about 190 euros, but both us and the other guys.
Speaker Change: So that's encouraging we should see good adoption there.
Speaker Change: And then the rest of the world.
Speaker Change: The basic elements of RSV the morbidity mortality.
Speaker Change: These are very apparent I think one thing that we're watching is just different geographies to emphasizing all the adults are the ones more focused on the channel. So for example.
Speaker Change: In.
Speaker Change: In Latin America is more focused on the Internalizes, Australia, whereas the European Mark small focused on older adults, including Japan. So early days, but I think we've got a pretty good idea of the pricing point.
Speaker Change: As said earlier sit out.
Speaker Change: K tender.
Canada was very very price intensive.
Speaker Change: Whole strategy.
Speaker Change: In Q2, we want to play the longer term game, we have the best in class vaccine, we have accumulated a very clear picture on the benefit risk and the potency and the duration of effect. So now we're moving to contract.
Speaker Change: Thankfully I mean I think.
Speaker Change: As you can see in our reported sales international RSV sales are still a very small fraction.
Speaker Change: And in fact in the U S. I think there's still a.
Speaker Change: 80% of those the ace it.
She is able to have no vaccinated this way for the reasons that may run through.
Speaker Change: It's a tougher yet this year.
Immediately the benefit of this vaccine all the data that surrounds it.
Speaker Change: <unk> will come when you look at the widening the concentrate but yes, it's right there.
[laughter] exit to decide what.
Speaker Change: All of that.
Speaker Change: And when you look at west shouldn't mixes with nearly 60% of the business.
Speaker Change: Coming internationally, there is plenty of room.
Speaker Change: Penetration of this high performing banks at that time.
Speaker Change: Next question. Please the next question is from Simon Baker Simon.
Simon Baker: Thank you Jeff.
Simon Baker: Pretty cool everyone. Two questions. If I may please firstly on <unk> could you remind us.
Simon Baker: Assumptions in terms of severity of asthma are assumed within the peak sales number how far down the continuum of severity.
Simon Baker: Do you expect to go to get number.
Simon Baker: And then secondly, a question on.
Simon Baker: Which might be equal.
Simon Baker: If we have more terminal congestion in pharmacies, and we have a vaccine that has multi year efficacy what is the fee.
Simon Baker: Feasibility of shifting the time of vaccination from the autumn to earlier in the year to at least mitigate issue that you've run into.
Sean: Thanks, Sean.
Sean: Thanks.
One is the seasonal I think if that's a word.
Sean: The way I think when we get to combo vaccines, but you're obviously GSK wants to compete in that would also help in terms of share of Goldman space.
Sean: But perhaps you can comment on that and then Tony will come to you in terms of the profile of ethics and.
Sean: Yes.
I think you've hit the nail on the head there.
Sean: It's tough right now we are exceeding the cost for the reasons, we know maybe primarily because of.
Sean: The direction that ICF has given.
Sean: Terms of narrowing the Clos.
Sean: On the basis of benefit of risks.
Sean: We think this will adjust the time for reasons that I'll go through in a minute.
Sean: Chinese texting each other as we watch the.
Sean: The FDA presentation.
Sean: And the benefit risk slide slide 10.
Sean: Which said that.
Sean: For every million people that you vaccinate over a three year period.
Sean: In the existing 75, plus $6 74 at risk, it's about 2000 less deaths.
Sean: <unk> thousand less hospitalizations and the trade off is zero to 18 or about non GBS cases.
Sean: I think that will start to assert itself.
Sean: The time, when we look at co administration with RSV, even just recently.
Sean: It is really quite striking.
Sean: In August.
Sean: <unk>, 56% of the Thomas given with another vaccine that jumped to 71% in September.
Sean: And what is remarkable if you look at what it was given with an August it was fluid 24% of the time.
In September that was 12%.
Sean: And what really was it was 3% with kind of it in August and that jumped to 10%.
In September 24, what is really interesting is the triplet.
Sean: Flu combination that went from 5% of our exited shops in August 27%.
Sean: In September so what that tells me is there is an opportunity as we did with <unk>.
Sean: We've got more work to do we're seeing rates, but as we did with shipments to be seasonal as this vaccine and because of this longer window, which again thats what promises tell us they want.
Sean: In terms of just managing their workflow staffing levels et cetera.
We will get there in the mid to long term with this vaccine imperative that I mab.
Speaker Change: I don't think we have given the penetration rates, but if you look at biological penetration it is still disappointingly logs.
Speaker Change: It's about a third was just under a third of people who are actually eligible for a biologic and its not an access issue.
Essentially pulmonologists thing willing and allergists as well too to prescribers.
Speaker Change: <unk> in those patient groups.
Speaker Change: What is what is attractive about the market remember when we do our market research is that first of all you've got this part B paper Bravo dimension of Bondo component, which is not as prominent with new Carla.
Speaker Change: And then we will look at market rates.
The recent market research are at about 80% of IC page are extremely interested in that six months protocol.
Speaker Change: And about 58% said they would use it naive patients.
Speaker Change: And about two thirds I don't consider switching.
Speaker Change: And then when we look at patients around 60% sorry, six six months is a lot more attractive and just got the 90% would actually consider.
Speaker Change: Doctor recommended it sucks.
Speaker Change: That translates to about a 20% jump in our models anyway.
Speaker Change: Market research I mean, that's not really going to do it but about a 20% uplift in biologic use because of that efficacy frequency trade offs, let's say.
Speaker Change: The other thing is we've got all of the with the exception of COPD lifecycle coming within two years of the initial approval, which is very different from you call it which was around six years.
Think about 'twenty.
Speaker Change: Just to sort of assignment.
Speaker Change: Think about it.
Speaker Change: Switzerland with two studies of course were designed to look at reduction of exacerbations.
Speaker Change: Standard of care.
Speaker Change: The primary endpoint across both of those are always the message of 64% reduction that's what we should have expected remember we were matching.
Speaker Change: Relative to call it, but just a few tidbits to.
Speaker Change: Digging into the details of the fed is going to say so.
Speaker Change: The quality of that wont come out in terms of administration.
Speaker Change: Frequency to build on Luka coins.
Speaker Change: You also see from for example in the.
Speaker Change: And pre specified analysis.
Speaker Change: Okay.
Speaker Change: I can transfer exacerbations, requiring hospitalization or.
Speaker Change: 72% reduction, but actually if you look across those with <unk>.
Speaker Change: To realize another study 68% of the patients on <unk> experienced no exacerbations at all I mean.
Speaker Change: Thank.
Speaker Change: And then moving towards next question, but this is not this.
Speaker Change: Demonstration of capability from GSK on the value to patients and health care professionals of a long acting medicine as we see in our HIV business.
Speaker Change: To keep people out of hospital and improve compliance as well as just being more user friendly is yeah, I think a very exciting field test for us to continue to pursue and will contribute meaningful Greg next question. Please.
Speaker Change: The next question is from Graham Parry from Bank of America branch.
Graham Parry: Great. Thanks for taking my question. So just on direct see looking into 2025.
Graham Parry: No I was just wondering what sort of cadence you would expect it to stage penetration.
Graham Parry: Should we be thinking increases like the 6% to 7% that we saw.
Graham Parry: Switching to the addressable populations receiving that expansion of that.
Graham Parry: And would that therefore leads to a drop in the U S. Next year and then the extent to which you think international can offset this if you're going to start getting some scope for launching two international territories, which which I assume but if you could confirm would be based on pricing for at least three seasons duration given you have that data now.
Graham Parry: And then secondly on <unk> could you just help us understand at what level of inventories as high as holding now and whether you expect to sell any more into say inventory in 2024.
Graham Parry: <unk> is the 400, essentially not going to be minimal contract people, even though going to be achieved and then your confidence in achieving the $800 million.
Graham Parry: She believed going forwards. Thank you.
Graham Parry: So.
Speaker Change: Thanks Glenn.
Speaker Change: Just repeat what we've said on China in terms of analytics edge in terms of theory.
Speaker Change: Contracts that we have but all commitments take a long view very.
Speaker Change: Ambitious.
Speaker Change: And then perhaps you can comment more on our rec stay in terms of.
Speaker Change: Ambitions that hedge was going to be out of the early fill appeals both are international and frankly U S penetration and don't forget Graham This is an unusually.
Speaker Change: Slow season.
Speaker Change: Not sure we're going to be forecasting that as a long term projection considering once you look at the last 15 years, but.
Speaker Change: Do you want to comment on penetration.
I think Graham.
Speaker Change: <unk>.
Speaker Change: The unpredictable component here is what <unk> does.
Speaker Change: And they remain cautious I wonder requires the FDIC figures, but I think that they are important.
Speaker Change: The question is what happens with the rest of this year.
Speaker Change: Maybe.
Speaker Change: Typically it's November is the classical RSVP, if that has changed since COVID-19.
Speaker Change: But I think that's important that's informative also just can I sort of get comfortable about the benefit risk here as they get more data from this season and look at the overall benefit risk.
Speaker Change: If you look at the penetration rates.
Speaker Change: Bye bye grid in.
Speaker Change: In December $23, 75, plus was 17%.
Speaker Change: As of August, which is our most recent data that's up from 21%. So you've got the effects of the June I sit there and that 29 million people.
Speaker Change: Paper population.
Speaker Change: And if you look at the 60 to 74 that is definitely slowing.
Speaker Change: So that was 10% at the end of last year and it's about 14%.
Speaker Change: In August 2000 trades, so that's the population to watch.
Speaker Change: Pretty clear.
Speaker Change: In quarter, two that that was not good news.
In terms of what have been said around that population.
Speaker Change: There are other views on that but we felt that that would be or Todd.
Speaker Change: The uptake and I think the evidence is better than the other.
Speaker Change: The swing factor is the 50 to 59 in the 19 plus population. So I think it's really.
Speaker Change: It's quite difficult to.
Speaker Change: Forecast.
Speaker Change: 2025 with Rex.
Speaker Change: <unk>.
Speaker Change: On it.
Still a lot more confident about the mid to long term.
Speaker Change: Because of all the elements that we've covered.
Speaker Change: I would say 25 is going to be chat.
Speaker Change: Challenging until I ship normalize.
Speaker Change: Okay.
Speaker Change: There is a clear signal sent there and I think I'd see phase of it.
Speaker Change: Let's hope over time, the evidence in terms of benefit risk.
Speaker Change: It's the same for what it is and I will tag stopped so I'll stop there were a couple of other not trying to if you wanted to add anything else I mean, just to build on on that.
Speaker Change: That's sort of unpack some of the headline conclusions from discrimination.
Speaker Change: Conversations and let me start where you finished <unk>.
Speaker Change: While they concluded in the recommended and approved and recommended population is the benefit risk is.
Speaker Change: It's proven unclear.
Speaker Change: It was in fact, a commentary that the confidence intervals kidney.
Speaker Change: <unk> delivery will continue to lead.
Speaker Change: Strong profitable growth in 'twenty, five and underpinned.
Hi confidence alongside the five approvals, we're expecting and hoping to get by the end of the year underpinned a serious confidence in all of the long term outlook sweeping.
Speaker Change:
Speaker Change: We committed to and increase at the beginning of this year. So can I have a short term challenge to digest.
Speaker Change: But fundamentally.
Okay.
Speaker Change: It's been building alongside the progress in the pipeline always more to do.
Speaker Change: That means that we see.
Speaker Change: <unk> and our vaccines business.
Speaker Change: Continuing to drive the transformation of the shape of GSK annual service performance next question. Please.
Speaker Change: The next question is from Emmanuel Papadakis Manuel.
Speaker Change: Yeah.
Emmanuel Papadakis: Thank you Sir.
Emmanuel Papadakis: I'm, sorry, I'm going to ask another question on RSV.
Emmanuel Papadakis: Goodbye.
Speaker Change: How are you going to get to 3 billion peak I mean, even with a modest degree of.
Speaker Change: The late degree vaccination in the U S. It doesn't seem like a return to blockbuster territory in the USA. So is this really a statement about international potential or are we missing something on the U S. What are the assumptions the St.
Speaker Change: We can get $3 billion.
Speaker Change: Can I perhaps.
Speaker Change: Sure.
Speaker Change: Quick question on plan, maybe a more favorable.
Speaker Change: <unk> talked about the timelines of the U S. Do you anticipate your priority review.
Speaker Change: Onto the FCA General series of adventure.
Speaker Change: Can you comment on the relaunch expectations commercially for next year with relatively modest set of consensus expectations. They love to hear what you think about those thank you.
Speaker Change: Thanks.
Speaker Change: I think he can say compared today, so I'm just going to reiterate very briefly there are 64 million people that suffer from RSA on a seasonal basis.
Speaker Change: 15000 people die every year in America.
Speaker Change: Brand, new vaccine with a cautious ace it but yes.
Speaker Change: But I do have to hold us.
Speaker Change: So this trade off again, just being realistic about the care quality and those elements and the actual impact on the patient.
Speaker Change: Flexibility around the dosing, we know a lot more about this product now.
Speaker Change: And the opening opportunity in second line with the progression of G City I sit into into the first one so you add all those things plus we've got a huge amount of experience clinically and also commercially zoned organization over the years I think the dream a dream <unk> designs are evidence of that as there's no more turmoil.
Speaker Change: And everybody humble about it we're carefully working with the experts but.
Speaker Change: But I think we are increasingly well placed to do this product justice.
Speaker Change: Subject to the FDA approving it.
Speaker Change: And I think also at the end of the year, if we were able to achieve the Bible.
Speaker Change: Well that will obviously support the product.
Speaker Change: In that in that second line setting.
Speaker Change: Next question please.
Speaker Change: The next question is from Richard Parkes, Richard or Jason.
Richard Parkes: Hi, Thanks for taking my questions, Firstly, just to push a little bit on the confidence in the Rx fee re vaccination mark Okay. Because you seem very confident about that but it looks like the decline in vaccine efficacy.
Richard Parkes: Somewhat stabilized in June it sounds like Ace it wasn't fully convinced by your re vaccination Immunogenicity data. So just can you just underline why you're so confident about that and maybe what impact that would have on your peak sales assumptions. If it is not didn't materialize and then secondly on CT tubes.
Richard Parkes: Launch looks like it's lost a little bit of momentum and could you just discuss what drives it from here.
Richard Parkes: Hum prep market penetration is and how your thinking has evolved over contribution of prep teal long acting cell's target. Thank you very much.
Speaker Change: So Tony on way back some then yes.
Richard Parkes: Yes.
Richard Parkes: Just quickly on <unk>.
Richard Parkes: As you see that data, particularly in the lower respiratory tract disease population show that there is a decline since season once the season three of 83% in season, one and two I think 48% in season, three importantly, and to answer your question with regards to the trajectory Richard We also know that natural infection.
Richard Parkes: <unk> does not cause lifetime immunity.
These mucosal infections, you don't see that and so we think that the available evidence Saturday. So it suggests that <unk> will be reclined and it will be between three and five yes.
Richard Parkes: Please take the opportunity to stress so what we also see through that and you'll see more data from us next year.
Richard Parkes: Boosting both there is a clear trend.
Richard Parkes: Again, as Colin would be the case in vaccines that as the time from trying to boost extends the significance of the boost increases. Thank you.
Speaker Change: But I think to say just to start by saying they are up slightly.
Speaker Change: They like to buy.
Speaker Change: Performance in the quarter with the HIV franchise 12 to take place.
Speaker Change: And we think that what they take place each quarter throughout the Esa sauce, I'm really happy with the way our trajectory on.
Speaker Change: Take care.
Speaker Change: <unk> is that progressing but on stereo two drug regimens are also doing extremely well.
Because just don't that picture. So I think it's worth remembering that 22 billion.
Speaker Change: Market value in HIV is about.
Speaker Change: Billions of treatment.
Speaker Change: Is that correct.
Speaker Change: So you normally expect big numbers and HIV, because we are usually operating in the treatment space, but I'd say you got to remember that this is a 2 billion market keeps grabbing a relatively rapidly so between 10 and 15% of the amendment in the U S. So the growth is strong the market is robust.
Speaker Change: And I appreciate you staying well set with things that continue to grow we saw 95% right in the ports are and I'd say, it's in line with our expectations. We are building a market here. So you know.
Speaker Change: And showing that physicians understand the safety and efficacy tolerability.
Speaker Change: This exceptional prevention.
Speaker Change: Medicine, but at the same time, we're having to teach to teach physicians I think about it the market around how to navigate a specialty pharmacy pine belt and the other kind of areas that you signed with Injectables in the U S health care market and we are investing very strongly with thing.
Speaker Change: Really good breadth of prescribing increases.
Speaker Change: Justin I appreciate actually but we've kept the neighborhood as well. So my summary would be there's still a long way to go and in this market on treatment longer injectables are really growing rapidly.
Speaker Change: <unk> are not driving our growth in a very positive way, which is why we've been able to deliver three quarters of a.
Speaker Change: Double digit growth this year and obviously, we had a very strong performance driven by the same things and 22 and 23 as well so real confidence in our long acting injectable space This year and actually for next year as well on the pipeline coming through on the pipeline coming forward. So obviously, we've got Q4 N a prep.
Speaker Change: Treatment coming up and then we've got Oh every six months, which is progressing.
Speaker Change: Absolutely in line with our expectations I will obviously come to talk more about that as data emerges. Thank you I think one last question.
Speaker Change: We have time for one final question and we're going to go to Peter Welford from Jefferies and Peter we really have to limit. This to just one question instead of two so if you can pick your best one that'd be great.
Speaker Change: Oh, sorry.
Speaker Change: Uh huh.
Speaker Change: I wouldn't just sorry, if we can just go back to Rex right.
Talk a little bit about D C and I'm, just trying to understand beyond the safety side of things because I can't see you see seems like a bit of a stimulus.
Speaker Change: Situation in that the obviously the.
Speaker Change: Population so they can make a better characterization of the GPS race is relatively low given the low number of vaccinations and obviously FDA already has the data with regards to the risk side of the equation I E. The number of deaths and hospitalizations for the 60 to 70 before so it seems.
Speaker Change: Do you like your conclusion, essentially the reasons significant GBS risk eventually.
Speaker Change: So I guess I'm curious what you see how do you see more data about population will potentially make a difference in what you can I guess provide incrementally to box to sway sway them on that population. Thank you.
Speaker Change: I think we will finish up then with Chinese response on this but just to reiterate our confidence has been this hasn't been set by all of the team.
Speaker Change: And the benefit risk ratio. This this vaccine.
Speaker Change: Considering the disease hospitalization.
Speaker Change: Absolutely yes.
Speaker Change: Peter Let me just so for me that the headline as I said for Asia was first of all the clear conclusion that the benefit risk for vaccination in the currently approved and recommended to the population was substantiated substantiated by increasingly clean data on both.
Speaker Change: Benefits and the risks associated with operations in terms of.
Speaker Change: And again, let me stress the FCA completion, that's dog to you guys.
With one less case.
Speaker Change: Less than 10 cases, sorry per million individuals' vaccinate.
Speaker Change: In the broader cases, what you will see us, bringing additional data related to vaccine effectiveness for the 60 plus population and Immunogenicity.
Speaker Change: <unk> plus immune compromised populations, particularly in those constitute.
Speaker Change: Populations of dollar greater risk of hospitalization.
Speaker Change: And isn't it also relates to say Tony that.
Speaker Change: Pound for frequency of vaccination, that's no different here, but yes. It was a comparison made on the IRR for flu for example, and if you account for the frequency of vaccination in fact, the flu itself causes GBS, there's no significant difference and risks across those vaccination. Thank you very much. So thanks, everyone for joining.
Speaker Change: Nicole I see.
Speaker Change: We're delighted to be Reconfirming our.
Our guidance for the year another year of strong operating performance.
Speaker Change: Football nuts.
Speaker Change: And also our confidence in the outlook for 2006 and two.
Speaker Change: He won the poet's catching up with you in the coming days. Thank you Goodbye.